Precision medicine is revolutionizing airway disease management by tailoring treatments to individual patient characteristics, including clinical, genetic, environmental, and lifestyle factors. This personalized approach enhances therapy efficacy, minimizes adverse events, and reduces healthcare costs. Recent technological advances have identified biomarkers that refine diagnoses, improve risk stratification, and guide therapeutic strategies, leading to better outcomes for patients with asthma, chronic obstructive pulmonary disease (COPD), and bronchiectasis. This CME course explores the latest scientific evidence, emphasizing optimal integration of recent advances into clinical practice.

By Participating, You Will Be Able To:

• Summarize the scientific evidence supporting recent advances in asthma management and describe their optimal use in clinical care.
• Critically review the research on alpha-1 antitrypsin deficiency and its links to asthma, chronic obstructive pulmonary disease, and bronchiectasis.
• Describe the scientific evidence on airway disease including imaging studies and physiologic insights, nontobacco exposure effects, and bronchoscope interventions.
• List the current and developmental pharmacotherapies for COPD, their mode of action, therapeutic targets, safety and efficacy data, and potential use in clinical practice.

Who Should Attend?

The education is designed for pulmonologists, critical care and internal medicine/primary care physicians, geneticists, fellows, clinician scholars, and any other clinician, including nurses, physician assistants, and pharmacists primarily managing asthma and COPD patients.